Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group reported a 12.3% decrease in total revenue and a 7.1% decline in reported profit for the first nine months of 2025 compared to the previous year. The finished drugs segment, which experienced a 17.2% revenue drop, was notably impacted by industry policies like centralized volume-based procurement and drug price adjustments. Despite these challenges, the company saw growth in bulk products and functional foods, indicating a shift in market dynamics.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating within the pharmaceutical industry. The company focuses on the production and sale of finished drugs, bulk products, and functional foods, with a significant emphasis on therapeutic areas such as the nervous system, oncology, and anti-infectives.
Average Trading Volume: 150,391,035
Technical Sentiment Signal: Buy
Current Market Cap: HK$90.53B
See more insights into 1093 stock on TipRanks’ Stock Analysis page.